Inside Amylyx's headquarters in Cambridge, MA (courtesy Amylyx)
Amylyx to voluntarily withdraw ALS drug Relyvrio after Phase 3 fail, will lay off around 70%
Amylyx announced Thursday morning that it will pull its ALS drug Relyvrio from the US and Canadian markets.
The decision comes as Amylyx will also …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
